これは2022-07-26 09:28:56 UTCで公開された古いバージョンです。最新バージョンをお読みください。
プレプリント / バージョン1

Infectiousness in omicron BA.2 (B.1.1.529.2) an effectiveness of the fourth vaccination BA.2 in Japan


  • Kurita, Junko Department of Nursing, Faculty of Sports & Health Science ,Daitoubunka University
  • Tamie Sugawara Infectious Disease Surveillance Center, National Institute of Infectious Diseases
  • Yasushi Ohkusa Infectious Disease Surveillance Center, National Institute of Infectious Diseases




COVID-19、 effective reproduction number、 omicron、 vaccine coverage、 vaccine effectiveness、 BA.2


Background: Omicron variant strain dominated since the beginning of 2022. Its infectivity was supposes to be higher than Delta variant strain or strains in past. Moreover, the fourthe vaccination had started in May, 2022.

Object: We estimated prevalence of omicron variant strain, particularly BA.2 (B.1.1.529.2) variant and COVID-19 vaccine effectiveness of the third dose in Japan as well as controlling for waning of second dose of vaccine, other mutated strains, the Olympic Games, and countermeasures.

Method: The effective reproduction number R(t) was regressed on shares of omicron variant strain and BA.2 and vaccine coverage of the third dose, as well as along with data of temperature, humidity, mobility, share of the other mutated strains, and an Olympic Games and countermeasures. The study period was February, 2020 through February 21, 2022, as of March 15, 2022.

Results : Estimation results indicated that waning of the second dose vaccine e with 150 days prior was the most appropriate specification.  Moreover, BA.2 of omicron variant strain has higher infectively than other variant strain or traditional strain.

Discussion: Because of data limitation since emerging BA.2, the estimated its infectively will change over time.

ダウンロード *前日までの集計結果を表示します



Araf Y, Akter F, Tang YD, Fatemi R, Parvez MSA, Zheng C, Hossain MG. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol 2022. 94:1825-32.

Ren SY, Wang WB, Gao RD, Zhou AM. Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance. World J Clin Cases 2022.10:1-11. doi: 10.12998/wjcc.v10.i1.1.

Zhou H, Tada T, Dcosta BM, Landau NR. Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal Antibodies. bioRxiv 2022.2022.02.15.480166. doi: 10.1101/2022.02.15.480166.

Cheng VC, Ip JD, Chu AW, Tam AR, Chan WM, Abdullah SMU, Chan BP, Wong SC, Kwan MY, Chua GT, Ip P, Chan JM, Lam BH, To WK, Chuang VW, Yuen KY, Hung IF, To KK. Rapid spread of SARS-CoV-2 Omicron subvariant BA.2 in a single-source community outbreak. Clin Infect Dis 2022.ciac203. doi: 10.1093/cid/ciac203.

Fonager J, Bennedbak M, Bager P, Wohlfahrt J, Ellegaard KM, Ingham AC, Edslev SM, Stegger M, Sieber RN, Lassauniere R, Fomsgaard A, Lillebaek T, Svarrer CW, Moller FT, Moller CH, Legarth R, Sydenham TV, Steinke K, Paulsen SJ, Castruita JAS, Schneider UV, Schouw CH, Nielsen XC, Overvad M, Nielsen RT, Marvig RL, Pedersen MS, Nielsen L, Nilsson LL, Bybjerg-Grauholm J, Tarpgaard IH, Ebsen TS, Lam JUH, Gunalan V, Rasmussen M. Molecular epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November 2021 to 2 January 2022. Euro Surveill 2022.27:2200181. doi: 10.2807/1560-7917.ES.2022.27.10.2200181.

Prime Minister and his Cabinet. Novel Coronavirus Vaccines. https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html (in Japanese) (accessed Nov 30, 2021)

Japan Ministry of Health, Labour and Welfare. Situation of vaccine coverage for COVID-19. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_sesshujisseki.html (in Japanese) (accessed Nov 30, 2021)

Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med 2021:NEJMoa2114583.

Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021:NEJMoa2114114.

Leung K, Shum MHH, Leung GM, Lam TTY, Wu JT. Early transmissibility assessment of the alpha variant strain of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro Surveill 2021;26:2002106.

Graham MS, Sudre CH, May A, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health 2021;6:e335-e345.

Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 2021;372(6538): eabg3055.

Zhao S, Lou J, Cao L, Zheng H, Chong MKC, Chen Z, Chan RWY, Zee BCY, Chan PKS, Wang MH. Quantifying the transmission advantage associated with alpha variant strain substitution of SARS-CoV-2 in the UK: an early data-driven analysis. J Travel Med 2021;28:taab011.

Hoang VT, Al-Tawfiq JA, Gautret P. The Tokyo Olympic Games and the Risk of COVID-19. Curr Trop Med Rep 2020;1-7.

Anzai A. “Go To Travel” Campaign and Travel-Associated Coronavirus Disease 2019 Cases: A Descriptive Analysis, July–August 2020. J. Clin. Med 2021;10:398. https://doi.org/10.3390/jcm10030398

Shi P, Dong Y, Yan H, Zhao C, Li X, Liu W, He M, Tang S, Xi S. Impact of temperature on the dynamics of the COVID-19 outbreak in China. Sci Total Environ. 2020;728:138890.

Tobias A, Molina T. Is temperature reducing the transmission of COVID-19? Environ Res. 2020;186:109553.

Yao Y, Pan J, Liu Z, Meng X, Wang W, Kan H, Wang W. No association of COVID-19 transmission with temperature or UV radiation in Chinese cities. Eur Respir J. 2020;55:2000517.

Walrand S. Autumn COVID-19 surge dates in Europe correlated to latitudes, not to temperature-humidity, pointing to vitamin D as contributing factor. Scientific Reports 2021;11:1981.

Kurita J, Sugishita Y, Sugawara T, Ohkusa Y. Mobility data can reveal the entire COVID1-19 outbreak course in Japan. JMIR Public Health & Surveillance 2021;7. https://publichealth.jmir.org/2021/2/e20335

Bergman N, Fishman R. Mobility Reduction and Covid-19 Transmission Rates. https://www.medrxiv.org/content/10.1101/2020.05.06.20093039v3

Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, Whittaker C, Zhu H, Berah T, Eaton JW, Monod M, Imperial College COVID-19 Response Team; Ghani AC, Donnelly CA, Riley S, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 2020;584:257-61.

Li Y, Campbell H, Kulkarni D, Harpur A, Nundy M, Wang X, Nair H, for theUsher Network for COVID-19 Evidence Reviews (UNCOVER) group. The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries. Lancet Infect Dis 2021;21:193–202

Larrosa JMC. SARS-CoV-2 in Argentina: Lockdown, mobility, and contagion. J Med Virol 2020.;93:2252-61.

Japan Ministry of Health, Labour and Welfare. Press Releases. https://www.mhlw.go.jp/stf/newpage_10723.html (in Japanese) (accessed Jan18, 2022).

Kurita J, Sugawara T, Ohkusa Y. Estimated effectiveness of school closure and voluntary event cancellation as COVID-19 countermeasures in Japan. J Infect Chemother 2021;27:62-4. doi: 10.1016/j.jiac.2020.08.012.

Sugishita Y, Kurita J, Sugawara T, Ohkusa Y. Effects of voluntary event cancellation and school closure as countermeasures against COVID-19 outbreak in Japan. PLOS One 2020.

Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility – King County, Washington, March 2020. Morb Mortal Wkly Rep 2020;69:377-81.

Tokyo metropolitan Government. Data of COVID-19 monitoring meeting in metropolitan Tokyo. https://www.bousai.metro.tokyo.lg.jp/taisaku/saigai/1013388/index.html (in Japanese) (accessed April 21,2022)

Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603-15.

Chung H, He S, Nasreen S, et al. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ 2021;374.

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernan MA, Lipsitch M, Reis B, Balicer RD. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412-23.

Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 2021;397:1646-57.

Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, Simmons R, Cottrell S, Roberts R, O'Doherty M, Brown K, Cameron C, Stockton D, McMenamin J, Ramsay M. Effectiveness of the Pfizer–BioNTech and Oxford–AstraZeneca vaccines on Covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 2021;373:n1088.

Bjork J, Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F. Effectiveness of the BNT162b2 vaccine in preventing COVID-19 in the working age population: first results from a cohort study in southern Sweden. Infect Dis (Lond) 2021;1-6.

Pawlowski C, Lenehan P, Puranik A, Agarwal V, Venkatakrishnan AJ, Niesen MJM, O'Horo JC, Virk A, Swift MD, Badley AD, Halamka J, Soundararajan V. FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Med (N Y) 2021;2:979-92.e8.

Li B, Deng A, Li K, et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. medRxiv 2021.07.07.21260122; doi: https://doi.org/10.1101/2021.07.07.21260122



投稿日時: 2022-07-25 05:01:51 UTC

公開日時: 2022-07-26 09:28:56 UTC